Table 2.
Clinical presentation, pre-hospital and in-hospital variables in total population and subgroup of patients in 3 different timeline periods.
| Mid-March to mid-May 2019 (Group A) (60 patients) |
January to mid-March 2020 (Group B) (54 patients) |
Lockdown period from mid-March to mid-May 2020 (Group C) (53 patients) |
P-value | |
|---|---|---|---|---|
| Angiographic variables | ||||
| Anterior STEMI, %(n) | 46.7 (28) |
31.5 (17) |
50.9 (27) |
0.10 |
| 2 or 3 vessels disease, %(n) | 55.0 (33) |
50.0 (27) |
39.6 (21) |
0.27 |
| Final TIMI 3 | 93.3 (56) |
96.3 (52) |
86.8 (46) |
0.17 |
| Number of stents used >1 | 46.7 (28) |
47.8 (22) |
39.6 (21) |
0.71 |
| Reperfusion treatment time delays | ||||
| Beginning of symptoms to FMC, median [IQR] min | 103.0 [42.5, 263.0] |
91.0 [38.0, 235.5] |
189.0 [70.0, 840.0] |
0.007 |
| FMC to first device activation, median [IQR] min | 104 [87.0, 146.0] |
99.5 [80.0, 150.0] |
102 [73.0, 133.0] |
0.37 |
| Arrival to hospital to first device activation, median [IQR] min | 71.0 [42.5, 108.5] |
59 [40.0, 101.0] |
63 [35.0, 104.0] |
0.66 |
| Clinical endpoints | ||||
| MACE, % (n) | 5.0 (3) |
11.1 (6) |
22.6 (12) |
0.02 |
| Mechanical complications, death and shock, % (n) | 1.7 (7) |
3.7 (2) |
13.2 (1) |
0.03 |
| Mechanical complications, % (n) | 0.0 0 |
1.9 1 |
9.4 5 |
0.02 |
| Death, % (n) | 1.7 (1) |
0.0 (0) |
9.4 (5) |
0.02 |
| Stent thrombosis, % (n) | 0.0 (0) |
1.9 (1) |
0.0 (0) |
0.35 |
| Reinfarction, %(n) | 0.0 (0) |
0.0 (0) |
0.0 (0) |
– |
| Malignant arrhythmia, % (n) | 0.0 (0) |
5.6 (3) |
11.3 (6) |
0.03 |
| Cardiogenic shock, % (n) | 3.3 (2) |
0.0 (0) |
3.8 (2) |
0.37 |
| Target-vessel urgent revascularization, % (n) | 1.7 (1) |
1.9 (1) |
11.3 (6) |
0.03 |
| Stroke, % (n) | 0.0 (0) |
0.0 (0) |
0.0 (0) |
– |
Values are given as % (n), mean ± standard deviation or median [IQR] when appropriate.
FMC, first medical contact; MACE, major adverse cardiac events; STEMI, ST-elevation myocardial infarction.